Litcius/Paper detail

Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis

Kun Tian, Jiaqi Han, Zhu Wang, Jie Chen

2022Oral Oncology20 citationsDOI

Topics & Concepts

MedicineOncologyQuality-adjusted life yearCost effectivenessInternal medicineChemotherapyNasopharyngeal carcinomaProgression-free survivalImmunotherapyRadiation therapyCancerRisk analysis (engineering)Head and Neck Cancer StudiesCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas